Q-omics provides the consensus-scored ACTL6B profile across patient tissues and cancer cell-line models. ACTL6B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACTL6B is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, ACTL6B protein abundance shows 14,075 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where ACTL6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTL6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTL6B survival associations across molecular data types. ACTL6B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTL6B RNA expression–survival associations across cancer types. High ACTL6B expression shows unfavorable associations in KIRC, COAD and UCS, but favorable associations in LGG, BLCA and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACTL6B RNA expression.
This table summarizes ACTL6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ACTL6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTL6B shows lower tumor expression in COAD and THCA and higher tumor expression in LIHC, LUSC, KIRC and UCEC. The COAD box plot shows higher ACTL6B RNA expression in normal versus tumor tissue (log2 FC = −0.317, t-test p < 0.001).
This table shows molecular features associated with ACTL6B in patient tissues and cancer cell lines. In patient samples, ACTL6B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACTL6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_SCLC.
